5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Venus Remedies Ltd.

•
venusremedies.com / www.vmrcindia.comBSE: 526953NSE: VENUSREM
Market Cap₹ 2,182 Cr.
Current Price
High / Low₹ 2,044 / 424
Stock P/E19.3
Book Value₹ 535
Price to Book1.60
Dividend Yield0.61 %
ROCE20.4 %
ROE15.5 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 118.4% YoY, showing strong momentum
  • Operating margins have improved to 18.7% from 13.3%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.48x)
  • Working capital cycle has improved - days down from 156 to 118
  • Company generates healthy free cash flow

CONS

  • Valuation is stretched - P/E of 19.3 is well above its own 5-year median (11.1)
  • Though reporting repeated profits, the company pays out little dividend (13.5%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.VENUSREM1632.2518.782181.830.6122.97139.27178.8635.6021.8819.12
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
99170131175106170172197132193180259179
8515711815492157150171119163143200149
Operating Profit13131321141323251330375930
OPM %13.66%7.71%9.91%12.15%13.49%7.61%13.11%12.83%9.59%15.49%20.41%22.95%16.81%
23242812482253
Interest0000000000000
Depreciation7666665466667
Profit before Tax810919101529251526335833
Tax %47.14%44.67%10.20%35.75%55.85%37.47%17.98%40.43%20.48%24.84%24.05%24.51%21.69%
Net Profit458134924151219254326
3.254.076.139.363.336.9218.0211.078.7514.4018.6432.5119.10

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
375355302320515577538575644769810
328312268277468508476514569625654
Operating Profit474434434769626175144156
OPM %12.60%12.27%11.36%13.45%9.11%11.93%11.44%10.59%11.64%18.72%19.25%
31-4-54181011261111
Interest3635251313000000
Depreciation3933333134333126222525
Profit before Tax-25-23-28-64145404779131149
Tax %18.38%-13.49%4.07%-31.36%-32.18%-9.66%28.18%34.62%33.53%24.00%23.85%
Net Profit-20-27-27-8544929315399113
EPS0.000.000.000.0043.9737.1221.6722.8239.3274.29—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%13.46%—

COMPOUNDED SALES GROWTH

10 Years:
7%
5 Years:
8%
3 Years:
13%

COMPOUNDED PROFIT GROWTH

10 Years:
55%
5 Years:
13%
3 Years:
51%

STOCK PRICE CAGR

10 Years:
33%
5 Years:
27%
3 Years:
91%
1 Year:
257%

RETURN ON EQUITY

10 Years:
4%
5 Years:
10%
3 Years:
10%
Last Year:
16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 7

₹ 1

Rs.10.0000 per share(100%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital12121212121313131313
382356329320374436465495576676
27825522515448393939011
Trade Payables312733346850495269111
6599132124444044425565
Total Liabilities767748732644547578609641713876
389370347271244225200203214215
Capital Work in Progress66656525252526212651
2900000201984238
140136141136120126114118100129
00000009099116
Cash & Bank3411305053687828
14017417821012715219612311199
Total Assets767748732644547578609641713876

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
6252446310941283583151
Cash from Investing-18-11-11-556-17-51-7-76-182
Cash from Financing-44-40-35-72-162-9000-1
00-212615-23287-32

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
41.7641.7641.7641.7641.7641.7641.7641.7641.76
1.061.181.111.342.251.862.252.802.92
0.000.000.000.000.110.751.031.200.89
Government0.000.000.000.000.000.000.000.000.00
57.1857.0657.1356.9055.8955.6354.9654.2454.43

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Copy of Newspaper Publication

2026-09-10 - Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-09
Copy of Newspaper Publication

2026-09-09 - Venus Remedies Limited has informed the Exchange about newspaper publication of notice to physical shareholders for transfer of physical shares as per SEBI circular.

2026-09-07
Updates

2026-09-07 - Venus Remedies Limited has informed the Exchange regarding Social Media Post on awareness on transfer of physical shares ''.

2026-08-21
Shareholders meeting

2026-08-21 - Voting Results and Scrutinizer's report. Earlier submitted file was not machine readable.

2026-08-21
Shareholders meeting

2026-08-21 - Venus Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 20, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-21
Amendment to AOA/MOA

2026-08-21 - Venus Remedies Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.

2026-08-20
Appointment

2026-08-20 - Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. Gurminder Singh Bedi as Non- Executive Independent Director of the company w.e.f. May 26, 2026.

2026-08-20
Appointment

2026-08-20 - Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director of the company w.e.f. October 01, 2026.

2026-08-20
Appointment

2026-08-20 - Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. (Mrs.) Savita Gupta as Non- Executive Independent Director of the company w.e.f. December 30, 2026.

News

Recent coverage and analyst commentary for VENUSREM

Loading news…

🤖

AI Stock Analyst

Venus Remedies Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login